Prescriber Scope of Practice for Anxiety

If you’re a psychiatrist or psychiatric nurse practitioner treating anxiety disorders via telehealth, you’re practicing in a regulatory landscape that’s been in flux since 2020 — and it’s still shifting. Between federal DEA rules, state-specific prescribing laws, and evolving practice authority for NPs, staying compliant while delivering quality anxiety care requires keeping multiple regulatory balls in the air.

Let’s cut through the noise and talk about what actually matters for your practice.

The Federal Reality: DEA Extensions and the Ryan Haight Question

Here’s the good news: as of 2025, you can still prescribe controlled anxiety medications via telehealth without requiring an initial in-person visit. The DEA and HHS extended COVID-era telehealth flexibilities through December 31, 2025, meaning providers can initiate benzodiazepines and other Schedule II-V controlled substances through telemedicine encounters.

This wasn’t a given. In 2023, the DEA proposed reinstating the Ryan Haight Act’s in-person requirement — a move that would have forced psychiatrists to see anxiety patients face-to-face before prescribing medications like alprazolam or clonazepam. After receiving over 38,000 public comments (many from mental health providers pointing out this would devastate access to care), the DEA backed off and instead extended the temporary rules while promising a ‘new path forward for telemedicine.’

What this means for your practice:

• You can legally prescribe benzodiazepines, stimulants for comorbid ADHD, and other controlled medications after a telehealth-only evaluation
• The evaluation must meet standard of care — typically live video, thorough psychiatric assessment, documented diagnosis
• This flexibility expires December 31, 2025, unless extended again
• You should prepare for potential rule changes: the DEA may eventually require some form of in-person assessment for ongoing controlled substance prescribing

The compliance essentials:

• You need a DEA registration in your state of practice
• Document your telehealth encounter as thoroughly as an in-person visit
• Check your state’s Prescription Drug Monitoring Program (PDMP) as required (more on this below)
• Use DEA-compliant e-prescribing systems with two-factor authentication for controlled substances

The uncertainty is frustrating, but for now, telehealth prescribing for anxiety remains viable. Just stay alert for DEA announcements in late 2025.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists: Full Scope, State-Specific Hurdles

As a psychiatrist, your scope of practice is straightforward: you can independently diagnose and treat any anxiety disorder, prescribe any medication (controlled or not), and provide therapy. No state limits what a licensed physician can do for anxiety treatment.

The regulatory complexity isn’t about scope — it’s about geography and prescribing compliance.

Multi-State Licensing

You must be licensed in every state where your patients are located. A psychiatrist in California treating a patient in Texas via video is practicing medicine in Texas and needs a Texas license. Period.

The Interstate Medical Licensure Compact (IMLC) helps here. Texas, Illinois, Pennsylvania, and Florida are member states — if you hold a license in one IMLC state, you can expedite getting licenses in others. California and New York are not in the compact, so you’ll go through their standard licensing processes.

Multi-state licensure is often the biggest barrier for psychiatrists wanting to scale a telehealth practice. Platforms like Klarity typically assist with this, but budget time and money for the process.

State PDMP Requirements Are Non-Negotiable

Every state with controlled substance prescribing has a Prescription Drug Monitoring Program, and most mandate checking it before prescribing benzodiazepines or other controlled medications:

• New York’s I-STOP law: You must check the state PMP registry before every Schedule II, III, or IV prescription. That means before writing that first Xanax script and before each refill.
• Pennsylvania: PDMP check required before initial benzodiazepine or opioid prescription and for each subsequent prescription (essentially every time you write a benzo script).
• Florida: Check E-FORCSE before prescribing any Schedule II-V controlled substance and at least every 90 days for ongoing therapy.
• California: CURES database check required at least every 4 months for patients on Schedule II-IV medications.
• Texas: Mandatory PMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.

These aren’t suggestions — state boards audit compliance, and failing to check PDMPs before prescribing controlled substances is one of the fastest routes to disciplinary action. Most EHR systems now integrate PMP access, making this a 30-second task per patient.

E-Prescribing Is Essentially Universal

As of 2025, nearly every state requires or strongly encourages electronic prescribing for controlled substances. California and New York mandate e-prescribing for all medications (controlled or not). Paper prescriptions for controlled substances require special tamper-proof pads in most states and are being phased out.

Telehealth platforms should equip you with compliant e-prescribing software. If you’re running your own practice, ensure your system meets DEA’s Electronic Prescribing for Controlled Substances (EPCS) requirements.

PMHNPs: Scope Varies Wildly by State

If you’re a psychiatric nurse practitioner, your ability to independently treat anxiety and prescribe medications depends heavily on which state you’re practicing in. The regulatory landscape for NPs ranges from full autonomy to mandatory physician oversight.

Full Practice States (or Nearly There)

Illinois and New York have moved to full practice authority for experienced NPs:

• Illinois: NPs with 4,000+ hours of clinical experience and additional training can apply for Full Practice Authority. Once granted, you can practice independently, including prescribing — though if you’re prescribing Schedule II opioids in your first 5 years of FPA, you need a physician consultation relationship in place. For anxiety meds (mostly Schedule IV benzos and non-controlled SSRIs), no physician involvement required.

• New York: After 3,600 hours of practice under physician collaboration, NPs can practice fully independently. The 2022 law made this permanent — experienced PMHNPs in NY now run their own practices without collaborative agreements.

• California: In transition. AB 890 created pathways for NP independence starting in 2023 for certain settings (like group practices). By January 2026, qualified NPs can practice fully independently in all settings. If you’re an experienced PMHNP in California, you’re about to have significantly more autonomy.

Restricted Practice States: Collaboration Required

Texas, Florida, and Pennsylvania require physician oversight for NP practice:

• Texas: You must have a Prescriptive Authority Agreement (PAA) with a physician. The agreement outlines your scope and which medications you can prescribe. One physician can supervise up to 7 NPs in most cases.

• Florida: PMHNPs must practice under a supervisory protocol with a physician (often a psychiatrist). The 2020 law granting some NPs independent practice specifically excluded psychiatric specialists — it only applied to primary care NPs. You need that physician protocol on file.

• Pennsylvania: Collaborative agreement with a physician required. The physician doesn’t need to be on-site but is officially responsible for oversight. PA hasn’t passed NP independence legislation as of 2025.

For telehealth platforms, this means they need physician collaborators available in restrictive states. In autonomous states, deployment is simpler — an experienced PMHNP can see patients without coordinating physician sign-offs.

Controlled Substance Prescribing: Extra Layers for NPs

While virtually all states allow PMHNPs to prescribe Schedule IV benzodiazepines (the most common anxiety medications), there are often additional restrictions:

Schedule II Limitations:

• Texas: APRNs cannot prescribe Schedule II drugs in outpatient settings except in hospitals or hospice care. So you cannot independently prescribe stimulants for comorbid ADHD via telehealth in Texas — a physician must do that.

• Florida: NPs can prescribe Schedule II, but only up to a 7-day supply unless you’re a certified psychiatric nurse treating mental illness. The psychiatric specialist exemption allows longer prescriptions for psychiatric conditions (like ADHD stimulants for anxiety patients with comorbid ADHD).

Schedule III-IV (Benzodiazepines):

• Pennsylvania: NPs can prescribe Schedule IV (benzos) for up to 90 days per prescription under a collaborative agreement. Schedule II limited to 30-day supply.

• Most states permit NP prescribing of benzodiazepines with physician collaboration or under FPA. The practical difference is whether you need the collaborating physician’s name on the prescription or can prescribe under your own authority.

All PMHNPs prescribing controlled substances need:

• A DEA registration
• State controlled substance license (if your state requires one — Illinois and Florida do)
• Compliance with the same PDMP checking requirements as physicians
• E-prescribing systems meeting DEA standards

The Bottom Line for NPs

State-specific scope rules mean you need to know your practice environment cold. A Texas PMHNP cannot prescribe the same Schedule II medications as a New York PMHNP with full practice authority. Telehealth platforms handle this by ensuring collaborative agreements are in place where needed and restricting formulary options in restrictive states.

The trend is toward autonomy — over half of states now have full or reduced practice authority for NPs. But the largest states by population (CA, TX, FL, PA) still have restrictions, meaning most patients live where PMHNPs face some regulatory limitations.

State-Specific Telehealth Prescribing Rules You Can’t Ignore

Beyond scope of practice, each state has its own telehealth rules that affect how you can evaluate patients and prescribe medications:

California

• No mandatory in-person exam for prescribing via telehealth if standard of care is met
• Telehealth exam (even asynchronous questionnaires combined with video) can satisfy ‘appropriate prior examination’ requirements
• CURES PDMP check required for Schedule II-IV drugs at least every 4 months
• E-prescribing required for all prescriptions as of 2022
• Not in IMLC — you need a full CA license to practice there

Texas

• Telehealth allowed if you establish care via synchronous audio-visual exam (no initial audio-only for new patients)
• Teleprescribing controlled substances permitted except for chronic pain management (Schedule II for chronic pain requires in-person evaluation)
• Anxiety treatment is exempt from the chronic pain restriction — you can prescribe benzos for panic disorder via telehealth
• Mandatory PDMP check for opioids, benzos, barbiturates before prescribing
• Texas is in IMLC for physician licensure

Florida

• Explicit ban on Schedule II teleprescribing except for four situations: psychiatric treatment, inpatient care, hospice, or nursing home residents
• This means psychiatrists can prescribe Adderall or other Schedule II via telehealth for ADHD/anxiety, but the same doctor couldn’t prescribe Schedule II for non-psychiatric uses remotely
• Must obtain written patient consent for telehealth treatment
• E-FORCSE PDMP check required before any Schedule II-V controlled substance prescription
• Out-of-state telehealth registration available: you can register to practice in Florida without a full FL license if you meet eligibility requirements

New York

• No state-imposed in-person exam requirement — telehealth permitted for establishing care if standard of care met
• I-STOP PDMP: mandatory check before every Schedule II, III, or IV prescription (including each benzodiazepine refill)
• E-prescribing required for all medications since 2016
• Not in IMLC — separate NY license required
• NPs with 3,600+ hours can practice fully independently as of 2022

Pennsylvania

• No comprehensive telehealth statute until insurance law passed in 2024, but boards permit telemedicine if standard of care met
• Real-time interactive audio-video recommended for initial evaluations
• PDMP check required before initial prescription of any opioid or benzodiazepine and for each subsequent prescription
• E-prescribing mandatory for controlled substances (with limited exceptions) since 2019
• PA is in IMLC for physicians
• NPs still require collaborative agreements — independence legislation hasn’t passed

Illinois

• Telehealth friendly — no in-person exam requirement
• Audio-only telehealth explicitly permitted for mental health services if patient can’t access video
• PDMP check required for Schedule II prescriptions; strongly encouraged for benzos
• State controlled substance license required in addition to DEA registration
• Illinois joined IMLC (2018) and Nurse Licensure Compact for RNs (2022)
• Full Practice Authority available for experienced NPs

The Economics of Telehealth Anxiety Practice: Realistic Expectations

Let’s talk about the business side, because regulatory compliance only matters if you’re building a sustainable practice.

The DIY marketing reality: Acquiring anxiety patients through your own marketing is expensive and time-consuming. If you’re considering building your own telehealth practice and handling patient acquisition yourself, here’s what you’re actually looking at:

• SEO takes 6-12 months of consistent investment (content, technical optimization, backlinks) before generating meaningful patient flow. Most solo providers don’t have the expertise or patience for this.

• Google Ads for mental health keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+, and that’s after months of testing and optimization.

• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+ depending on specialty), but when you factor in the monthly subscription, total cost per acquired patient adds up quickly.

• Total DIY marketing cost: When you factor in agency/consultant fees, ad spend, staff time to handle and qualify leads, no-show rates from cold leads, months of SEO investment, and failed campaigns, acquiring a qualified psychiatric patient costs $200-500+ per patient through traditional marketing channels.

The platform alternative: Klarity Health and similar telehealth platforms use a different model — you pay a standard fee per new patient appointment (similar to Zocdoc’s per-booking fee) instead of gambling on marketing channels.

Why this matters economically:

• No upfront marketing spend or monthly subscriptions burning cash while you build patient volume
• Pre-qualified patients already matched to your specialty and availability — not cold leads you have to screen
• No wasted ad spend on clicks that don’t convert or SEO campaigns that take months to yield results
• Built-in telehealth infrastructure (no separate platform costs, e-prescribing, EHR integration)
• Both insurance and cash-pay patient flow, diversifying your revenue
• You control your schedule — only pay the listing fee when a qualified patient books with you

Instead of spending $3,000-5,000/month on marketing with uncertain results and a 6-12 month timeline to patient flow, you pay only when a qualified patient books. That’s guaranteed ROI vs. gambling on marketing channels you may not have expertise in.

Can DIY marketing eventually be cost-effective? Absolutely — if you have the budget to sustain 6-12 months of losses, expertise in healthcare SEO and PPC, and patience to test and optimize campaigns. For most providers, especially those starting out or scaling, a platform that handles patient acquisition removes the risk entirely.

Making Compliance Manageable: Practical Workflow Tips

Here’s how to integrate regulatory requirements without letting them bog down your practice:

For PDMP Checks:

• Use an EHR that integrates PDMP access directly — most modern systems let you query the database without leaving the patient chart
• Make it part of your prescribing workflow: assess patient → check PDMP → write prescription → document check
• In states requiring checks for every prescription (like PA for benzos), build in 30 seconds per refill

For Multi-State Practice:

• Start with 2-3 states where you see the most demand or have the easiest licensing path
• Use IMLC if eligible (covers TX, IL, PA, FL among the priority states)
• For CA and NY, budget 3-4 months and $1,000-2,000 per license for the standard application process
• Platforms like Klarity often assist with licensing logistics and can advise on which states to prioritize

For Documentation:

• Template your telehealth consent language so it’s captured at intake
• Document the modality used (audio-visual vs. audio-only) and clinical justification
• Note PDMP check and any findings in the patient chart
• For prescriptions, document diagnosis, rationale, and discussion of risks/benefits just as you would in person

For NPs in Collaborative States:

• Ensure your collaborative agreement explicitly covers anxiety treatment and the specific medications you’ll prescribe (including benzodiazepines if applicable)
• Keep physician contact information current and maintain required communication logs
• Understand your state’s limits on controlled substance prescribing and stay within them — platforms should configure your formulary accordingly

FAQ: Provider Questions About Anxiety Treatment Regulations

Can I prescribe benzodiazepines after a telehealth-only evaluation in 2025?

Yes, under the current DEA extension through December 31, 2025. You must conduct an appropriate telehealth evaluation (typically live video), document it thoroughly, and comply with state PDMP and e-prescribing requirements. Be prepared for potential rule changes after 2025 that may require an in-person component.

Do I need a separate license to practice telehealth across state lines?

You need a full medical or nursing license in each state where your patients are located. There’s no ‘telehealth-only’ license in most states (Florida has a telehealth registration for out-of-state providers, which is an exception). Use the IMLC if you’re a physician and the state is a member to expedite multi-state licensing.

What’s the difference between how psychiatrists and PMHNPs can treat anxiety?

Psychiatrists have full independent practice authority in all states — no supervision or collaboration required, and no restrictions on prescribing any medication (controlled or not). PMHNPs can also treat anxiety and prescribe medications, but state laws vary: some states grant full independence to experienced NPs, while others require physician collaboration. Some states (like Texas) prohibit NPs from prescribing Schedule II drugs in outpatient settings.

How often do I need to check the state PDMP?

It varies by state:

• New York: before every Schedule II-IV prescription
• Pennsylvania: before initial benzo/opioid prescription and each subsequent prescription
• Florida: before any controlled substance prescription and at least every 90 days
• California: at least every 4 months for patients on Schedule II-IV medications
• Check your state’s specific requirements — failure to comply is a common cause of board discipline.

Can I use audio-only (phone) visits for anxiety patients?

It depends. Some states (like Illinois) explicitly permit audio-only telehealth for mental health services if video isn’t accessible. However, for initial evaluations and especially for prescribing controlled substances, most states expect live video to meet standard of care. Audio-only might be acceptable for established patients or follow-ups, but check your state’s rules and federal DEA requirements (which currently require video for new controlled substance prescriptions in most cases).

What happens if DEA rules change after December 31, 2025?

The DEA is working on permanent telemedicine rules and has indicated a ‘new path forward’ after the 38,000+ public comments on its 2023 proposal. Possible outcomes include: maintaining current flexibility, requiring a hybrid model (initial telehealth prescription with in-person follow-up required), or implementing a special telemedicine DEA registration. Stay updated via DEA announcements and professional organizations. Platforms like Klarity will adapt compliance protocols to any new federal rules.

The Bottom Line: Compliance Is Complex, But Access to Care Matters

Navigating the regulatory landscape for anxiety treatment feels like practicing psychiatry in multiple jurisdictions at once — because you are. Federal DEA rules, state prescribing laws, multi-state licensing, PDMP requirements, and scope of practice variations create a complex compliance matrix.

But here’s why it matters: anxiety disorders affect 40 million U.S. adults annually, and the shortage of psychiatric providers means millions can’t access care. Telehealth dramatically expands access — if providers can navigate the regulations.

The key is building systems that make compliance manageable:

• Choose practice models (solo vs. platform) that match your risk tolerance and administrative capacity
• Focus on states where you can practice most efficiently given your credentials (psychiatrists have more flexibility; NPs should prioritize full-practice states)
• Integrate regulatory requirements (PDMP checks, documentation, e-prescribing) into your workflow so they’re routine, not burdensome
• Stay informed on rule changes, especially DEA telemedicine regulations as they evolve in 2025-2026

Whether you’re a psychiatrist with full prescriptive authority or a PMHNP navigating state-specific scope rules, telehealth platforms like Klarity can simplify the infrastructure — handling patient acquisition, multi-state compliance frameworks, and billing — so you can focus on clinical care.

Ready to expand your anxiety treatment practice via telehealth without the compliance headaches? Klarity Health provides the infrastructure, patient flow, and regulatory support you need. Explore joining Klarity’s provider network and start seeing patients in the states where you’re licensed — we handle the rest.

Citations and Sources

1. DEA & HHS Extend Telemedicine Flexibilities through 2025 – Drug Enforcement Administration Press Release, November 15, 2024. Available at: https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. §829(e)) – Federal controlled substance prescribing requirements. Referenced via Center for Connected Health Policy analysis at: https://www.cchpca.org/topic/online-prescribing/

3. Florida Statutes §456.47 – Telehealth Services – Florida Senate, 2025 edition. Available at: https://www.flsenate.gov/Laws/Statutes/2025/456.47

4. Texas Board of Nursing – APRN Prescriptive Authority FAQ – ‘Can an NP prescribe Schedule II in Texas?’ Updated December 9, 2025. Available at: https://www.bon.texas.gov/faqpracticeaprn.asp.html

5. New York State Department of Health – I-STOP/Prescription Monitoring Program Requirements – Mandatory PDMP consultation for Schedule II-IV prescriptions, effective August 27, 2013. Available at: https://health.ny.gov/professionals/narcotic/prescription_monitoring

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94